Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.56 Average Target Price from Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has received a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $17.56.

Several research firms recently weighed in on ATEC. Barclays boosted their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday. Needham & Company LLC boosted their target price on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th.

Insider Buying and Selling at Alphatec

In other news, EVP David Sponsel sold 58,283 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the completion of the transaction, the chief executive officer now directly owns 5,501,715 shares of the company’s stock, valued at approximately $66,020,580. This trade represents a 0.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,208 shares of company stock valued at $706,835. Company insiders own 22.80% of the company’s stock.

Institutional Investors Weigh In On Alphatec

Hedge funds and other institutional investors have recently bought and sold shares of the business. Envestnet Asset Management Inc. grew its position in shares of Alphatec by 5.8% in the second quarter. Envestnet Asset Management Inc. now owns 404,866 shares of the medical technology company’s stock valued at $4,231,000 after purchasing an additional 22,047 shares in the last quarter. Hsbc Holdings PLC boosted its stake in Alphatec by 130.1% in the 2nd quarter. Hsbc Holdings PLC now owns 33,403 shares of the medical technology company’s stock worth $347,000 after purchasing an additional 18,888 shares during the period. Sei Investments Co. grew its holdings in Alphatec by 4.7% during the 2nd quarter. Sei Investments Co. now owns 111,460 shares of the medical technology company’s stock valued at $1,165,000 after buying an additional 4,976 shares in the last quarter. Marshall Wace LLP increased its position in shares of Alphatec by 44.7% during the second quarter. Marshall Wace LLP now owns 1,099,692 shares of the medical technology company’s stock valued at $11,492,000 after buying an additional 339,832 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Alphatec by 65.2% in the second quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company’s stock worth $33,365,000 after buying an additional 1,260,137 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Down 5.7 %

Shares of NASDAQ:ATEC opened at $11.01 on Thursday. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -8.60 and a beta of 1.41. The business’s 50 day moving average is $9.92 and its 200 day moving average is $8.08. Alphatec has a 12-month low of $4.88 and a 12-month high of $17.34. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.